H35.3221

🧬 ICD-10-CM H35.3221 — Exudative AMD, Left Eye, Active CNV

Billable Code — No Warning Needed

ICD-10 CM H35.3221 is a valid, billable, fully specified 7-character ICD-10-CM code for FY2025. [web:138] All seven characters are present and meaningful: H35 (category) + .3 (degeneration of macula) + 2 (exudative) + 2 (left eye) + 1 (active choroidal neovascularization). This is the most clinically urgent code in the entire AMD family — active CNV is an ophthalmologic emergency driving immediate anti-VEGF treatment.

Active CNV = Ophthalmologic Urgency

ICD-10 CM H35.3221 represents active, leaking choroidal new blood vessels in the left eye. Without prompt anti-VEGF treatment, active CNV causes irreversible central vision loss within weeks. Any patient with new metamorphopsia (Amsler grid distortion), sudden central blur, or acute visual decline in the left eye requires same-day or next-day dilated examination, OCT, and evaluation for anti-VEGF initiation. This is not a routine follow-up diagnosis — it is the clinical equivalent of a STEMI for the retina.

Non-Billable Parent Codes

• ❌ H35.322 — 6-character header — missing stage character
• ❌ H35.32 — 5-character header — missing laterality AND stage Always submit H35.3221 (all 7 characters) for active wet AMD, left eye.

---

🔍 Code Description

ICD-10 CM H35.3221 classifies exudative (wet) age-related macular degeneration of the left eye with active choroidal neovascularization — the left-eye equivalent of H35.3211, representing the stage of wet AMD where CNV vessels are actively leaking fluid, blood, or lipid exudates into the subretinal or intraretinal space.

Active CNV is confirmed by the presence of subretinal fluid (SRF), intraretinal fluid (IRF), sub-RPE fluid, subretinal hyperreflective material (SHRM), or new subretinal hemorrhage on OCT — and/or active leakage on fluorescein angiography (FA) or OCT angiography (OCT-A). The diagnosis of “active CNV” is not a chronic stable state — it changes with treatment response. A patient may move from H35.3221 (active) to H35.3222 (inactive) as anti-VEGF treatment takes effect, and may revert to H35.3221 when fluid reactivates between injection intervals. The code must reflect the current activity status at each specific encounter, not a historical status.

---

🌳 Code Tree / Hierarchy — Left Eye Wet AMD Family

H35.32       Exudative AMD   ❌ Non-billable header
│
└── H35.322  Left Eye   ❌ Non-billable header
    │
    ├── H35.3220  Left eye, stage UNSPECIFIED   ⚠️ last resort
    ├── H35.3221  Left eye, ACTIVE CNV   ◀ THIS CODE ✅ URGENT
    ├── H35.3222  Left eye, INACTIVE CNV   ✅ post-treatment quiescent
    └── H35.3223  Left eye, INACTIVE SCAR   ✅ end-stage disciform

Left Eye vs. Right Eye — The Only Difference Is Laterality

Feature	Right Eye Active CNV	Left Eye Active CNV
ICD-10-CM Code	H35.3211	H35.3221
CPT Modifier	-RT	-LT
Laterality Character	1 (6th position)	2 (6th position)
Clinical Management	Identical	Identical
Anti-VEGF Drugs	Identical	Identical
J-Codes	Identical	Identical
Bilateral Code	H35.3231 if both eyes	H35.3231 if both eyes

The Only Difference Between H35.3211 and H35.3221 Is the Eye

All clinical guidance, anti-VEGF drug reference, J-code billing, staging logic, OCT interpretation, and treatment protocols from the H35.3211 note apply equally to H35.3221. The sole coding distinction is the 6th character (1 = right, 2 = left) and the -LT modifier on CPT/HCPCS codes. This note emphasizes left-eye-specific coding considerations, bilateral implications, and the active CNV clinical picture as the definitive reference for stage 1 in the H35.322x family.

---

📊 H35.3221 in the Wet AMD Staging Context

Complete Left-Eye Wet AMD Staging Reference

Code	Stage	OCT Findings	Fluid?	Anti-VEGF?	Clinical State
H35.3220	Unspecified ⚠️	Unknown	?	Cannot determine	Documentation deficiency
H35.3221	Active CNV ← This Code	SRF / IRF / SHRM / hemorrhage	✅ YES	✅ INJECT NOW	Ophthalmologic urgency
H35.3222	Inactive CNV	Fluid resolved, CNV membrane present	❌ No	Continue/extend interval	Treated/controlled
H35.3223	Inactive scar	Disciform fibrosis — fovea replaced	❌ No	Usually stopped	End-stage, irreversible

What “Active” Means on OCT — The Evidence Base for H35.3221

Active CNV is diagnosed when at least one of the following is present on OCT or imaging:

Finding	OCT Description	Clinical Significance
Subretinal fluid (SRF)	Hyporeflective space between photoreceptors and RPE	Fluid leaking from CNV into subretinal space — most common finding
Intraretinal fluid (IRF)	Cystoid hyporeflective spaces within retinal layers	Fluid within retina — often associated with type 3 RAP lesions
Sub-RPE fluid	Fluid beneath the RPE — pigment epithelial detachment (PED)	Common in type 1 (occult) CNV — often fibrovascular PED
Subretinal hyperreflective material (SHRM)	Hyperreflective material in subretinal space	CNV membrane itself or hemorrhage/fibrin
New subretinal hemorrhage	Hyperreflective or hyporeflective blood in subretinal space	Bleeding from fragile CNV vessels — urgent
Active leakage on FA	Pooling dye on fluorescein angiography	Gold standard for CNV activity confirmation
Flow signal on OCT-A	New or enlarged flow void/signal in outer retina	CNV vessel detection without dye

SRF vs. IRF — Clinical and Prognostic Significance

The type of fluid in active CNV has prognostic and treatment implications that are increasingly documented by retina specialists — and may appear in medical record documentation worth capturing:

• SRF only — generally more benign; some patients with small amounts of stable SRF may have CNV that is relatively “tolerant” of modest fluid accumulation under T&E protocols; some retina physicians accept small SRF as an acceptable endpoint under extended dosing
• IRF — associated with worse visual prognosis; most retina physicians treat to complete IRF resolution and do not accept persistent IRF as a stable endpoint
• Both SRF + IRF — worst prognosis for VA outcomes; aggressive treatment protocol

These distinctions don’t change the code (all are still H35.3221 — active CNV), but understanding them helps you recognize active vs. inactive CNV language in documentation and appreciate why the physician is treating aggressively even when vision appears preserved.

---

📋 Clinical Overview — Active CNV in Context

The CNV Activation Event

Active CNV in the left eye ( H35.3221) most commonly develops by one of two mechanisms:²

1. De novo conversion — left eye previously had intermediate or advanced dry AMD (H35.3122/H35.3124) and converts to wet AMD; often heralded by sudden metamorphopsia
2. Reactivation — previously treated left-eye wet AMD (H35.3222 inactive) flares; CNV re-activates with recurrent fluid between injection intervals

The distinction matters for clinical documentation and helps confirm code assignment:

• New conversion = first assignment of H35.3221 in the left eye; prior code was H35.312x (dry)
• Reactivation = code moves from H35.3222 back to H35.3221 at that encounter

Symptoms of Active CNV — Left Eye

Symptom	Details
Metamorphopsia	Straight lines appear wavy or distorted — Amsler grid distortion; the most specific early symptom
Central scotoma	Dark or blank spot in central vision left eye
Acute VA decline	Measurable drop from prior visit — even 1-2 Snellen lines warrants OCT
Micropsia	Objects appear smaller than normal — fluid distorting photoreceptor spacing
Color desaturation	Colors appear less vivid in the central field left eye
Asymptomatic	Rare but possible — especially with Type 1 occult CNV; detected on surveillance OCT

Asymptomatic Active CNV on OCT — Still Codes H35.3221

A patient under active T&E monitoring may present asymptomatic but have new subretinal fluid on OCT at a scheduled follow-up visit. This is still active CNV regardless of symptom status — the OCT findings drive the code, not patient-reported symptoms. If the physician injects based on OCT fluid detection alone, assign H35.3221. Do not assign H35.3222 simply because the patient says they “feel fine.”

The Fellow Eye Risk — Bilateral Vigilance

When H35.3221 is active in the left eye, the right eye must be simultaneously evaluated:

• If the right eye has any AMD (dry or wet), document and code its current status separately
• If right eye develops active CNV → assign H35.3211 alongside H35.3221 (bilateral active CNV — two separate laterality codes unless bilateral code H35.3231 better applies)
• Fellow eye conversion risk in a patient with one wet AMD eye is approximately 12% per year
• Both eyes’ AMD codes must reflect their independent current status — never use the same code for both eyes when staging differs

---

💊 Anti-VEGF Treatment — The Definitive Drug Reference for H35.3221

FDA-Approved Agents — Left Eye Protocol

Left Eye = -LT Modifier — The Critical Billing Distinction

Every CPT and HCPCS code billed for the left eye should carry the -LT modifier. This applies to 67028-LT (intravitreal injection) and — depending on payer — may also apply to drug J-codes. Verify your MAC’s policy on whether -LT is required on drug J-codes, as requirements vary. The injection CPT 67028-LT is universally required to distinguish from right eye billing when both eyes are treated (see bilateral injection scenario below).

Anti-VEGF Drug Reference Table — Current Agents (FY2025-2026)

Drug	Generic	HCPCS	Units to Bill	Dose	FDA Indication
Vabysmo	Faricimab-svoa	J2777	60 units	6mg/0.05mL	Wet AMD, DME [web:131]
Eylea 2mg	Aflibercept 2mg	J0178	1 unit	2mg/0.05mL	Wet AMD, DME, RVO
Eylea HD 8mg	Aflibercept 8mg	J0179	1 unit	8mg/0.07mL	Wet AMD — extended interval [web:128]
Lucentis 0.5mg	Ranibizumab 0.5mg	J2778	5 units	0.5mg/0.05mL	Wet AMD, DME, RVO, PDR [web:130]
Beovu	Brolucizumab-dbll	J0172	Per dose	6mg/0.05mL	Wet AMD
Susvimo	Ranibizumab implant	C9399	Port delivery	100mg/mL	Wet AMD — port delivery
Byooviz	Ranibizumab-nuna (biosimilar)	J2778	5 units	0.5mg	Biosimilar to Lucentis
Cimerli	Ranibizumab-eqrn (biosimilar)	J2778	5 units	0.5mg	Biosimilar to Lucentis
Yesafili	Aflibercept-jbvf (biosimilar)	Verify payer	Per dose	2mg	Biosimilar to Eylea
Bevacizumab	Bevacizumab (off-label)	J9035	Per dose — variable	Off-label	Compounded repackage

Beovu (Brolucizumab) — Retinal Vasculitis Risk — Document and Code Adverse Events

Beovu carries an FDA black box warning for retinal vasculitis and retinal vascular occlusion, including in the fellow eye. These are rare but vision-threatening adverse events that require urgent documentation and specific comorbidity coding. If retinal vasculitis develops in a patient receiving Beovu → code H35.06x (retinal vasculitis) or appropriate occlusion code alongside H35.3221 and report per FDA MedWatch requirements. This is a clinical documentation and coding alert that every retina practice using Beovu should have in their coding policy.

JZ / JW Modifier — Mandatory Since July 1, 2023

Missing JZ or JW = Claim Denial

Since July 1, 2023, CMS requires one of these modifiers on all separately billed drug J-codes: [web:130]

Modifier	Meaning	When to Use
-JZ	Zero units discarded — full dose administered	Standard — when entire vial used for one patient
-JW	Drug discarded — report waste	When a partial dose is used and remaining drug is discarded

Example correct billing for Vabysmo left eye, no waste: J2777-LT-JZ × 60 units

Example correct billing for Lucentis left eye, partial dose discarded: J2778-LT-JW (for wasted portion, separate line)

Practical tip for Crystal: The -LT modifier and -JZ modifier are both required on left-eye injection drug claims. Build them into your charge entry template so they don’t get missed. A single missing -JZ on a high-cost anti-VEGF claim can trigger a full audit.

---

🔄 The Active → Inactive → Active Cycle — Dynamic Code Assignment

One of the most important features of wet AMD coding is that H35.3221 and H35.3222 are not permanent assignments — they change visit-to-visit based on OCT findings:

NEW DIAGNOSIS ──► H35.3221 (Active CNV, loading × 3 injections)
                      │
              OCT: Fluid resolved
                      │
                      ▼
               H35.3222 (Inactive CNV — extend interval)
                      │
              OCT: Fluid returns at next visit
                      │
                      ▼
               H35.3221 (Active CNV — reactivation — inject again)
                      │
              OCT: Fluid resolved again — extend further
                      │
                      ▼
               H35.3222 (Inactive — now extended to q12 weeks)
                      │
           Disease eventually "burns out"
                      │
                      ▼
               H35.3223 (Inactive scar — disciform end stage)

The Code Changes at Every Visit — Check OCT Every Time

This dynamic cycle means that a patient who had H35.3222 (inactive) at their last visit may present as H35.3221 (active) today — and vice versa. The OCT report at each visit is the definitive authority. Never carry forward the prior visit’s code without confirming the current fluid status. This is one of the most common wet AMD coding errors: coding H35.3222 on a visit where the OCT shows recurrent fluid because the coder assumed the prior inactive status persisted.

---

🔭 Emerging Treatments — What’s Coming for H35.3221 (FY2026+)

The Anti-VEGF Landscape Is Actively Evolving — 2025-2026 Updates

The standard-of-care monthly/bimonthly intravitreal injection paradigm is being challenged by sustained-delivery and gene therapy approaches that may dramatically reduce injection burden for patients with H35.3221. These are not yet standard of care but are relevant for CDI and documentation awareness as they enter the clinical mainstream:

Treatment	Mechanism	Status (2025-2026)	Potential Coding Impact
ADVM-022 (ixo-vec)	AAV2.7m8 intravitreal gene therapy — continuous aflibercept expression	Phase 3 ARTEMIS trial enrolling	Single injection → sustained CNV suppression; H35.3221 active until sustained suppression confirmed; then H35.3222
ABBV-RGX-314	Suprachoroidal AAV gene therapy — anti-VEGF transgene	Phase 2/3 — 80% reduction in supplemental anti-VEGF injections	New HCPCS codes when approved; delivery CPT different from 67028
AXT107	Suprachoroidal integrin peptide — anti-VEGF-A/C + Tie2	Phase 1/2 DISCOVER trial	Novel delivery route — suprachoroidal injection may require different CPT
Port Delivery System (Susvimo)	Ranibizumab ocular implant — continuous intravitreal delivery	FDA approved — wet AMD and DME	Implantation CPT 67299 or 67027; refill J-code; different claim structure than injection
Bispecific/trispecific antibodies	Dual or triple pathway inhibition beyond VEGF+Ang-2	Multiple Phase 2 trials	New J-codes upon FDA approval

Gene Therapy Will Not Eliminate H35.3221 — It Will Change the Injection Frequency

If/when AAV gene therapy for wet AMD reaches approval, patients may still be coded as H35.3221 (active CNV) during the period between gene therapy administration and confirmed CNV suppression. H35.3222 (inactive) would be assigned when sustained suppression is achieved and no fluid is present. The diagnosis codes themselves are unlikely to change — but the CPT/HCPCS codes for the new delivery modalities will require monitoring as new permanent codes are assigned.

---

💰 HCC Risk Adjustment (CMS-HCC v28)

Field	Detail
CMS-HCC Model Version	v28 (2024-2025 Implementation)
HCC Assignment	❌ Not Mapped
HCC Category	N/A
RAF Coefficient	0.000

No direct HCC weight. However, H35.3221 encounters (monthly injections) are among the highest-frequency Medicare outpatient encounters — creating repeated comorbidity capture opportunities every 4-12 weeks throughout the year.

---

🏥 MS-DRG Assignment

MDC 02 — Diseases and Disorders of the Eye (if principal — extremely rare)

DRG	Title	Est. Relative Weight*
DRG 124	Other Disorders of the Eye with MCC	~0.95-1.15
DRG 125	Other Disorders of the Eye with CC	~0.70-0.90
DRG 126	Other Disorders of the Eye without CC/MCC	~0.50-0.70

*Verify against IPPS FY2025 Final Rule tables.

---

🔗 Related ICD-10-CM Codes

Complete Wet AMD Left-Eye Staging

Code	Stage	CNV?	Fluid?	Anti-VEGF?
H35.3220	Unspecified ⚠️	?	?	Cannot determine
H35.3221	Active CNV ← This Code	✅ Active	✅ YES	✅ INJECT
H35.3222	Inactive CNV	Quiescent	❌ No	Monitor/extend
H35.3223	Inactive scar	Scar	❌ No	Low vision

Bilateral Wet AMD — When Both Eyes Are Active

Situation	Code Assignment
Both eyes active CNV, same stage	H35.3231 — bilateral, active CNV — preferred if truly bilateral same stage
Left eye active H35.3221 + right eye active H35.3211	Either use H35.3231 bilateral or both separate codes — document bilateral
Left eye active H35.3221 + right eye inactive H35.3222	Separate codes required — asymmetric stages
Left eye active H35.3221 + right eye dry AMD H35.3112	Separate codes — different disease type/stage

Bilateral Injection Visit — Two Lines, Two Modifiers

When a patient receives bilateral same-day intravitreal injections (both eyes injected at the same visit):

• Bill 67028-RT (right eye injection) + 67028-LT (left eye injection) on separate claim lines
• Bill two separate drug J-code lines — one per eye
• Both with -JZ or -JW modifier per waste status
• Some MACs require modifier -50 (bilateral) instead of -RT/-LT— verify your MAC’s policy
• Bilateral same-day injections should be supported by OCT and clinical documentation for BOTH eyes showing activity justifying treatment of each eye

Concurrent Dry AMD — Dual Coding (Left Eye)

Code	Description	Co-Code When
H35.3123	Nonexudative AMD, left eye, advanced no subfoveal	GA and CNV co-existing in left eye
H35.3124	Nonexudative AMD, left eye, advanced subfoveal	Subfoveal GA co-existing with active CNV left eye
H35.3112	Nonexudative AMD, left eye, intermediate	Prior stage before wet conversion — retire and replace with H35.3221

Vision Impairment — Co-Code When VA Criteria Met

Code	Description	Threshold
H54.8	Legal blindness, as defined in USA	VA ≤20/200 or VF ≤20° in better eye
H54.12x	Blindness, left eye, various categories	VA ≤20/200 left eye — use laterality-specific code
H54.2x1	Low vision, left eye, category 1	VA 20/70-20/160 left eye
H54.2x2	Low vision, left eye, category 2	VA 20/200-20/400 left eye
H53.131	Sudden visual loss, right eye	—
H53.132	Sudden visual loss, left eye	Acute CNV onset — code at presentation if documented

---

🛠️ CPT / HCPCS — Standard Active CNV Left Eye Injection Visit

Template: Active CNV Left Eye — Anti-VEGF Injection Visit

Type	Code	Modifier(s)	Description
Injection procedure	67028	-LT	Intravitreal injection, left eye — always required
Drug: Vabysmo	J2777 × 60	-LT -JZ	Faricimab-svoa 6mg — no waste
Drug: Eylea 2mg	J0178 × 1	-LT -JZ	Aflibercept 2mg — no waste
Drug: Eylea HD	J0179 × 1	-LT -JZ	Aflibercept 8mg — no waste
Drug: Lucentis	J2778 × 5	-LT -JZ	Ranibizumab 0.5mg — no waste
OCT	92134	—	Fluid measurement — required every injection visit
Exam	92014	—	Established patient comprehensive exam
FA (if needed)	92235	—	Active leakage confirmation, CNV characterization

Template: Active CNV — New Wet AMD Diagnosis Visit (Initial Loading Dose #1)

Type	Code	Modifier(s)	Description
Exam — new patient	92004	—	New patient comprehensive — initial wet AMD evaluation
OCT	92134	—	Fluid and CNV characterization
FA	92235	—	CNV type and activity — standard at initial wet AMD diagnosis
Injection	67028	-LT	First loading dose injection, left eye
Drug	J-code	-LT -JZ	Selected anti-VEGF agent

Document "Loading Phase Injection #1 of 3" in the Record

At the first injection visit for newly diagnosed H35.3221, the physician’s documentation should note it is the first of three loading-phase injections. This documentation:

• Establishes the treatment protocol for the subsequent two loading visits
• Supports medical necessity for the next two monthly claims before the treat-and-extend or PRN protocol begins
• Creates an auditable treatment timeline that payers expect when reviewing anti-VEGF claim sequences

---

💊 Coding Scenarios

---

Scenario 1 — New Wet AMD Conversion, Left Eye (Outpatient)

Clinical Vignette: A 76-year-old female with known intermediate dry AMD, left eye (H35.3122) presents urgently — she noticed wavy lines when reading with her left eye starting 2 days ago. VA: 20/200 OS (was 20/30 six weeks ago). OCT left eye: large subretinal fluid collection with CNV membrane. FA: active type 2 classic CNV with leakage. Right eye: intermediate dry AMD, stable — VA 20/25 OD. Impression: “New wet AMD conversion, left eye — active CNV — initiating Vabysmo loading — urgent.” Vabysmo 6mg administered today.

CPT / HCPCS:

• 92004-LT (or 92014 if established) — Comprehensive exam
• 92235 — Fluorescein angiography (CNV characterization — standard at initial wet diagnosis)
• 92134 — OCT posterior segment (SRF confirmation, CNV measurement)
• 67028-LT — Intravitreal injection, left eye (Loading dose #1)
• J2777-LT-JZ × 60 units — Vabysmo 6mg, no waste

ICD-10-CM:

• H35.3221 — Exudative AMD, left eye, active CNV (converted from H35.3122 — wet AMD now confirmed; retire H35.3122 for this eye)
• H35.3112 — Nonexudative AMD, right eye, intermediate dry stage (right eye unchanged — separate active comorbidity)
• H53.132 — Sudden visual loss, left eye (2-day acute onset — separately codeable)

Retire H35.3122 When Left Eye Converts to Wet AMD

Once wet AMD is confirmed in the left eye, stop coding H35.3122 (intermediate dry) for the left eye and replace with H35.3221 (active CNV) going forward. The wet AMD code supersedes the prior dry AMD code for the converted eye. Only resume dry AMD coding for the left eye if the wet AMD resolves to scar (H35.3223) AND a separate GA lesion is also present (H35.3123/H35.3124).

---

Scenario 2 — Reactivation After 8 Weeks — Code Shifts Back to H35.3221 (Outpatient)

Clinical Vignette: A patient on Eylea T&E protocol — previously at 10-week intervals with resolved fluid. Returns at week 10. OCT left eye: new subretinal fluid at the fovea — approximately 150μm — new onset since last visit. VA unchanged from last visit (20/40 OS). Physician documents: “Reactivation of CNV, left eye — fluid recurrence — adjust interval back to 8 weeks — inject today.” Eylea HD administered.

CPT / HCPCS:

• 67028-LT — Intravitreal injection, left eye
• J0179-LT-JZ × 1 — Aflibercept 8mg (Eylea HD), no waste
• 92134 — OCT (fluid detection at this visit)
• 92014 — Comprehensive exam, established patient

ICD-10-CM:

• H35.3221 — Exudative AMD, left eye, active CNV (NOT H35.3222 — new OCT fluid confirmed today → this is active CNV, not inactive)

Code Reverts to H35.3221 on Reactivation — This Is Expected and Correct

The code appropriately moves from H35.3222 (at prior inactive visits) back to H35.3221 today because the OCT shows recurrent fluid. This is not a coding error — it reflects the dynamic nature of wet AMD. Both codes will appear in the patient’s encounter history, alternating with treatment response. This is normal and correct.

---

Scenario 3 — Bilateral Active CNV — Same-Day Bilateral Injection (Outpatient)

Clinical Vignette: A 79-year-old male with bilateral wet AMD — both eyes on monthly Lucentis loading phase. Today is loading dose #2 for both eyes. OCT both eyes: fluid present bilaterally. VA: 20/60 OD, 20/80 OS.

CPT / HCPCS:

• 67028-RT — Intravitreal injection, right eye (separate line)
• 67028-LT — Intravitreal injection, left eye (separate line)
• J2778-RT-JZ × 5 — Ranibizumab 0.5mg right eye, no waste
• J277]-LT-JZ × 5 — Ranibizumab 0.5mg left eye, no waste
• 92134 — OCT (bilateral — one code, document both eyes in report)
• 92014 — Comprehensive exam

ICD-10-CM:

• H35.3231 — Exudative AMD, bilateral, active CNV (both eyes active at same stage — bilateral code preferred)
• OR: H35.3211 + H35.3221 — Right active CNV + left active CNV (separate codes also acceptable — confirm payer preference)

Bilateral Code vs. Two Separate Laterality Codes — Both Are Acceptable

When both eyes have the same wet AMD stage, you may use either:

• H35.3231 (bilateral active CNV) — single code for both eyes; cleaner
• H35.3211 + H35.3221 (right active + left active) — separate codes; preferred by some payers who want explicit laterality on each claim line matching the -RT/-LT injection modifiers

Verify your payer’s preference. Some commercial payers and MACs prefer the bilateral code; others want to see the laterality-specific codes matched to the injection claim lines. When in doubt, separate laterality codes provide the clearest audit trail linking diagnosis to treatment side.

---

Scenario 4 — Wet AMD Left Eye Inpatient — Additional Diagnosis (Inpatient Cardiac)

Clinical Vignette: An 82-year-old female is admitted for NSTEMI, left main CAD. H&P documents active wet AMD, left eye — currently receiving Vabysmo injections every 8 weeks — last injection was 6 weeks ago. Ophthalmology consulted during admission to assess timing of next injection. VA OS 20/40. OCT done: “Stable minimal SRF — continue current T&E schedule.”

Principal Diagnosis:

• I21.02 — ST elevation MI, left main coronary artery (principal)

Additional Diagnoses:

• H35.3221 — Exudative AMD, left eye, active CNV (documented active condition, ophthalmology consulted, OCT performed — meets UHDDS criteria)
• I25.10 — Atherosclerotic CAD (left main disease)

"Stable Minimal SRF" — Is This Still H35.3221?

Yes. “Minimal SRF” on OCT still represents active CNV with fluid — the CNV is still leaking, even if the fluid volume is small and visually stable under T&E management. The code is H35.3221 (active) until OCT confirms complete fluid resolution (H35.3222 inactive). A T&E patient who has “stable SRF” by their retina physician’s treatment endpoint documentation is still technically H35.3221 at that visit. Some retina practices accept small stable SRF as an acceptable T&E endpoint — this can create ambiguity. When documentation says “stable, acceptable SRF — treat and extend” → query if active vs. inactive is intended, or use H35.3221 as clinically supported by the presence of fluid.

---

⚠️ Coding Pitfalls and Tips

	Pitfall or Tip
❌	Never carry forward H35.3222 (inactive) when today’s OCT shows new fluid — reactivation = H35.3221; check every visit
❌	Never code the prior dry AMD stage alongside H35.3221 unless GA co-exists — once converted, H35.3221 replaces the H35.312x dry code for that eye
❌	Never bill 67028 without -LT modifier for left eye — modifier is required for laterality identification and bilateral claim adjudication
❌	Never omit JZ or JW modifier on drug J-codes — claim denial since July 1, 2023
❌	Never use H35.3221 for non-AMD CNV — myopia-related CNV, POHS, angioid streaks, or other CNV etiologies have their own codes
✅	Read the OCT before assigning active vs. inactive — the presence or absence of fluid is the single most reliable determinant
✅	The injection decision is your fastest clue — injected today = active CNV = H35.3221 in the vast majority of cases
✅	Bilateral active CNV — use H35.3231 or separate laterality codes; know your payer’s preference
✅	Code vision impairment separately — H54.8, H54.12x when VA ≤20/200 left eye; don’t let VA data sit undocumented
✅	Update code dynamically — H35.3221 ↔ H35.3222 may alternate over the course of treatment; each visit’s code reflects that visit’s OCT
✅	Watch for gene therapy approvals — ADVM-022 and suprachoroidal platforms in late-phase trials; when approved, new CPT/HCPCS will be required for delivery procedures
✅	Document fellow eye AMD status separately — right eye AMD (whatever stage) must be independently coded at each encounter

---

📚 Sources

1. AAPC. “ICD-10 Code H35.3221 — Exudative AMD, left eye, with active choroidal neovascularization.” Confirmed billable FY2025. [web:138]

2. GenHealth.ai. “H35.3221 — Exudative AMD, left eye, with active choroidal neovascularization.” Left-eye family structure H35.3220-H35.3223; bilateral equivalent H35.3231; active CNV definition. [web:144]

3. MD Clarity. “ICD Diagnosis Code H35.3221: What It Is & When to Use.” Active CNV pathology — subretinal fluid, CNV mechanism, vision loss trajectory. [web:141]

4. CodeMap. ICD-10-CM H35.3221-H35.3222 left eye wet AMD family structure confirmation. [web:140]

5. UHCProvider. Ophthalmologic VEGF Inhibitors — Commercial Medical Drug Policy, April 1, 2026. Active CNV criteria for anti-VEGF authorization; untreated active CNV definition. [web:143]

6. Genentech Access Solutions. VABYSMO Wet AMD Billing Codes. J2777 × 60 units; -LT modifier; JZ modifier requirement. [web:131]

7. Genentech/Lucentis. Lucentis Wet AMD Billing Codes. J2778 × 5 units per injection. [web:130]

8. Retinal Physician. “Anti-VEGF and Beyond: Expanding Therapeutic Options for Wet AMD.” November/December 2025. ADVM-022 phase 3 ARTEMIS trial; ABBV-RGX-314 suprachoroidal gene therapy; bispecific and trispecific investigational agents. [web:148]

9. Retinal Physician / ClinicalTrials.gov. “Clinical Trial Update March 2026.” ADVM-022 (ixo-vec) Phase 3 ARTEMIS trial enrolling (NCT06856577); 80% injection reduction in LUNA trial. [web:146]

10. CMS. Billing and Coding: Aflibercept (EYLEA®) — Article A53387. J0178/J0179 unit assignments; -LT modifier application. [web:128]